Table 2.
Demographic and clinical characteristics of melanoma patients from whom plasma was collected.
| Case | Sex | Age (Years) | Stage a | LDH b | Previous Therapy | Targeted Therapy c | BR d | TTF e (Days) |
|---|---|---|---|---|---|---|---|---|
| Pt#1 | M | 57 | M1c | H | None | VEMU | PR | 223 |
| Pt#2 | M | 49 | M1c | H | None | VEMU | PR | 147 |
| Pt#3 | F | 74 | M1b | N | None | VEMU | PR | 195 |
| Pt#4 | M | 50 | M1a | N | None | VEMU + COBI | PR | 362 |
| Pt#5 | M | 58 | M1a | H | None | VEMU + COBI | PR | 195 |
a Stage at first plasma collection (i.e., T0). b LDH, lactate dehydrogenase; N, normal; H, >1.5 upper limit of normal values. c VEMU, vemurafenib, COBI, cobimetinib. d Best response according to RECIST 1.1 criteria: PR, partial response. e TTF, time-to-treatment-failure.